MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202641058010 A) filed by Saveetha Institute Of Medical And Technical Sciences on May 07, 2026, for Identification Of A Novel Drug Compound For Cervical Cancer Cyp1a1 ( Cytochrome p450 1a1) Using The.
Inventors include Venkatajothi Ramarao; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: Computational approaches to study interpretation and guidance help speed up the development of new medications for a range of human illnesses. Methodologies for computer-aided drug design (CADD) fall into two major categories: Ligand-Based Drug Design (LBDD) and Structure-Based Drug Design (SBDD). Cervical cancer is the fourth most common malignancy among women worldwide, accounting for approximately 660,000 new cases and 350,000 deaths in 2022. The goal of the current study is to create a possible anti-cancer medication that targets the CYP1A1 (cytochrome P450 1A1) protein, which is implicated in cervical cancer. The process of creating derivatives of chemical molecules involves the use of cheminformatics software and tools in conjunction with Computer Aided Drug Designing (CADD). Using molecular drug docking and toxicity assessment, the de novo structural design was verified. The entire set of findings made it abundantly evident that there may be pharmacological action in pharmacokinetic studies like ADMET (Absorption, Distribution, Metabolism, and Excretion/Toxicity). The developed new chemical inhibits the functional and structural domain sections of the mutant cervical cancer protein, CYP1A1, according to the drug docking data. Hence, this research work has proved that the de novo drug can be used as a potential therapeutic agent for cervical cancer.
Disclaimer: Curated by HT Syndication.
